Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin

Cell

Volumn 125, Issue 6, 2006, Pages 1179-1191

  Graham, Rona K ^a,b   Deng, Yu ^a,b   Slow, Elizabeth J ^a,b   Haigh, Brendan ^a,b   Bissada, Nagat ^a,b   Lu, Ge ^a,b   Pearson, Jacqueline ^a,b   Shehadeh, Jacqueline ^a   Bertram, Lisa ^a,b   Murphy, Zoe ^a,b   Warby, Simon C ^a,b   Doty, Crystal N ^a,b   Roy, Sophie ^c   Wellington, Cheryl L ^b   Leavitt, Blair R ^a,b   Raymond, Lynn A ^a   Nicholson, Donald W ^c   Hayden, Michael R ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 6; HUNTINGTIN; MUTANT PROTEIN; N METHYL DEXTRO ASPARTIC ACID; QUINOLINIC ACID; STAUROSPORINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME DEGRADATION; EXCITOTOXICITY; FEMALE; HUNTINGTON CHOREA; MOUSE; MOUSE STRAIN; NERVE CELL DEGENERATION; NERVE CELL LESION; NEUROPROTECTION; NEUROTOXICITY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

EID: 33745003424     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2006.04.026     Document Type: Article

References (39)

1. Albin R.L., Young A.B., Penney J.B., Handelin B., Balfour R., Anderson K.D., Markel D.S., Tourtellotte W.W., and Reiner A. Abnormalities of striatal projection neurons and NMDA receptors in presymptomatic Huntington's disease. N. Engl. J. Med. 322 (1990) 1293-1298
2. Albin R.L., Reiner A., Anderson K.D., Dure L.S., Handelin B., Balfour R., Whetsell Jr. W.O., Penney J.B., and Young A.B. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 31 (1992) 425-430
3. Auerbach W., Hurlbert M.S., Hilditch-Maguire P., Wadghiri Y.Z., Wheeler V.C., Cohen S.I., Joyner A.L., MacDonald M.E., and Turnbull D.H. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum. Mol. Genet. 10 (2001) 2515-2523
4. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., and Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321 (1986) 168-171
5. Bizat N., Hermel J.M., Humbert S., Jacquard C., Creminon C., Escartin C., Saudou F., Krajewski S., Hantraye P., and Brouillet E. In vivo calpain/caspase cross-talk during 3-NP-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. J. Biol. Chem. 278 (2003) 43245-43253
6. Bizat N., Galas M.C., Jacquard C., Boyer F., Hermel J.M., Schiffmann S.N., Hantraye P., Blum D., and Brouillet E. Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain. Neuropharmacology 49 (2005) 695-702
7. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., and Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997) 537-548
8. Eriksen J.L., Sagi S.A., Smith T.E., Weggen S., Das P., McLendon D.C., Ozols V.V., Jessing K.W., Zavitz K.H., Koo E.H., et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112 (2003) 440-449
9. Gafni J., Hermel E., Young J.E., Wellington C.L., Hayden M.R., and Ellerby L.M. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J. Biol. Chem. 279 (2004) 20211-20220
10. Graham R.K., Slow E.J., Deng Y., Bissada N., Lu G., Pearson J., Shehadeh J., Leavitt B.R., Raymond L.A., and Hayden M.R. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiol. Dis. 21 (2005) 444-455
11. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., and Li X.J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19 (1999) 2522-2534
12. Hackam A.S., Singaraja R., Wellington C.L., Metzler M., McCutcheon K., Zhang T., Kalchman M., and Hayden M.R. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J. Cell Biol. 141 (1998) 1097-1105
13. Hansson O., Petersen A., Leist M., Nicotera P., Castilho R.F., and Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to QA-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. USA 96 (1999) 8727-8732
14. Hermel E., Gafni J., Propp S.S., Leavitt B.R., Wellington C.L., Young J.E., Hackam A.S., Logvinova A.V., Peel A.L., Chen S.F., et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ. 11 (2004) 424-438
15. Hodgson J.G., Smith D.J., McCutcheon K., Koide H.B., Nishiyama K., Dinulos M.B., Stevens M.E., Bissada N., Nasir J., Kanazawa I., et al. Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. Hum. Mol. Genet. 5 (1996) 1875-1885
16. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23 (1999) 181-192
17. Iijima K., Liu H.P., Chiang A.S., Hearn S.A., Konsolaki M., and Zhong Y. Dissecting the pathological effects of human AB40 and AB42 in Drosophila: A potential model for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 101 (2004) 6623-6628
18. Jarabek B.R., Yasuda R.P., and Wolfe B.B. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 127 (2004) 505-516
19. Kim Y.J., Yi Y., Sapp E., Wang Y., Cuiffo B., Kegel K.B., Qin Z.H., Aronin N., and DiFiglia M. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl. Acad. Sci. USA 98 (2001) 12784-12789
20. Leavitt B.R., Raamsdonk J.M., Shehadeh J., Fernandes H., Murphy Z., Graham R.K., Wellington C.L., Raymond L.A., and Hayden M.R. Wild-type huntingtin protects neurons from excitotoxicity. J. Neurochem. 96 (2006) 1121-1129
21. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., et al. Enhanced sensitivity to NMDA receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58 (1999) 515-532
22. Lunkes A., Lindenberg K.S., Ben-Haiem L., Weber C., Devys D., Landwehrmeyer G.B., Mandel J.L., and Trottier Y. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell 10 (2002) 259-269
23. Ordway J.M., Tallaksen-Greene S., Gutekunst C.A., Bernstein E.M., Cearley J.A., Wiener H.W., Dure L.S., Lindsey R., Hersch S.M., Jope R.S., et al. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 91 (1997) 753-763
24. Rigamonti D., Sipione S., Goffredo D., Zuccato C., Fossale E., and Cattaneo E. Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J. Biol. Chem. 276 (2001) 14545-14548
25. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8 (1999) 397-407
26. Shehadeh J., Fernandes H.B., Zeron Mullins M.M., Graham R.K., Leavitt B.R., Hayden M.R., and Raymond L.A. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis. 21 (2005) 392-403 10.1016/j.nbd.2005.08.001 Published online September 13, 2005
27. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12 (2003) 1555-1567
28. Slow E.J., Graham R.K., Osmand A.P., Devon R.S., Lu G., Deng Y., Pearson J., Vaid K., Bissada N., Wetzel R., et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. USA 102 (2005) 11402-11407
29. Van Raamsdonk J.M., Murphy Z., Slow E.J., Leavitt B.R., and Hayden M.R. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 14 (2005) 3823-3835
30. Van Raamsdonk J.M., Pearson J., Slow E.J., Hossain S.M., Leavitt B.R., and Hayden M.R. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J. Neurosci. 25 (2005) 4169-4180
31. Van Raamsdonk J.M., Pearson J., Rogers D.A., Bissada N., Vogl A.W., Hayden M.R., and Leavitt B.R. Loss of wild type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 14 (2005) 1379-1392
32. Wellington C.L., Ellerby L.M., Hackam A.S., Margolis R.L., Trifiro M.A., Singaraja R., McCutcheon K., Salvesen G.S., Propp S.S., Bromm M., et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273 (1998) 9158-9167
33. Wellington C.L., Singaraja R., Ellerby L., Savill J., Roy S., Leavitt B., Cattaneo E., Hackam A., Sharp A., Thornberry N., et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem. 275 (2000) 19831-19838
34. Wellington C.L., Ellerby L.M., Gutekunst C.A., Rogers D., Warby S., Graham R.K., Loubser O., van Raamsdonk J., Singaraja R., Yang Y.Z., et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 22 (2002) 7862-7872
35. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., Li S.H., Yi H., Vonsattel J.P., Gusella J.F., et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet. 9 (2000) 503-513
36. Yu Z.X., Li S.H., Evans J., Pillarisetti A., Li H., and Li X.J. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J. Neurosci. 23 (2003) 2193-2202
37. Zeron M.M., Chen N., Moshaver A., Lee A.T., Wellington C.L., Hayden M.R., and Raymond L.A. Mutant huntingtin enhances excitotoxic cell death. Mol. Cell. Neurosci. 17 (2001) 41-53
38. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., and Raymond L.A. Increased sensitivity to NMDA receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860
39. Zhang Y., Li M., Drozda M., Chen M., Ren S., Mejia Sanchez R.O., Leavitt B.R., Cattaneo E., Ferrante R.J., Hayden M.R., and Friedlander R.M. Depletion of wild-type huntingtin in mouse models of neurologic diseases. J. Neurochem. 87 (2003) 101-106